What are the recommended acyclovir dosages for treating herpes simplex virus infections in adults, including adjustments for first‑time versus recurrent episodes and for impaired renal function?

Acyclovir Dosing for Herpes Simplex Virus Infections in Adults

First-Episode Genital Herpes

For first-episode genital herpes, treat with acyclovir 200 mg orally 5 times daily for 7-10 days or until clinical resolution. 1 This regimen significantly reduces duration of viral shedding, lesion healing time, and pain compared to placebo. 2

• Initiate therapy as early as possible – treatment started within the first 3 days of symptom onset provides the greatest clinical benefit. 3
• For herpes proctitis specifically, use a higher dose: acyclovir 400 mg orally 5 times daily for 10 days or until clinical resolution. 1
• Higher doses (4 g/day vs. standard 1 g/day) do not provide additional clinical benefit and may increase gastrointestinal side effects. 3

Recurrent Genital Herpes Episodes

For recurrent episodes, acyclovir 200 mg orally 5 times daily for 5 days is recommended, with alternative regimens of 400 mg three times daily or 800 mg twice daily for 5 days. 1

• Treatment must be initiated at the earliest sign of prodrome or within 24 hours of lesion onset to achieve any benefit. 1, 4
• Most immunocompetent patients with recurrent disease derive limited benefit from episodic treatment since early administration is rarely feasible. 1

Chronic Suppressive Therapy

For patients with frequent recurrences (≥6 episodes per year), use acyclovir 400 mg orally twice daily for continuous suppression. 1

• An alternative regimen of 200 mg orally 3-5 times daily can be used to identify the lowest effective dose for each patient. 1
• Suppressive therapy reduces recurrence frequency by at least 75%. 1
• After 1 year of continuous therapy, discontinue acyclovir to reassess the patient's recurrence rate, as frequency often decreases over time. 1
• Safety and efficacy have been documented for up to 5-6 years of continuous use. 1, 4, 1
• The dose of 200 mg four times daily provides longer time to first recurrence compared to lower doses or less frequent administration. 5

Severe Disease Requiring Hospitalization

For severe HSV infections with complications (disseminated disease, encephalitis, pneumonitis, hepatitis), administer acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution. 1

• This includes patients with extensive disease requiring hospitalization. 1

Herpes Zoster (Shingles)

For herpes zoster in adults, use acyclovir 800 mg orally 5 times daily for 7-10 days. 6

• Treatment must be initiated within 72 hours of rash onset, ideally within 48 hours for maximum benefit. 6
• Adults over 50 years show greater benefit from treatment. 6

Renal Impairment Adjustments

Dose adjustments are mandatory in renal impairment to prevent neurotoxicity. 6

Dosing by Creatinine Clearance:

For 200 mg every 4 hours (5x daily) regimen:

• CrCl >10 mL/min: 200 mg every 4 hours (no adjustment)
• CrCl 0-10 mL/min: 200 mg every 12 hours 6

For 400 mg every 12 hours regimen:

• CrCl >10 mL/min: 400 mg every 12 hours (no adjustment)
• CrCl 0-10 mL/min: 200 mg every 12 hours 6

For 800 mg every 4 hours (5x daily) regimen:

• CrCl >25 mL/min: 800 mg every 4 hours (no adjustment)
• CrCl 10-25 mL/min: 800 mg every 8 hours
• CrCl 0-10 mL/min: 800 mg every 12 hours 6

For hemodialysis patients: Administer an additional dose after each dialysis session, as dialysis removes approximately 60% of plasma acyclovir over 6 hours. 6

For peritoneal dialysis: No supplemental dose is needed after adjusting the dosing interval. 6

Critical Caveats

• Maintain adequate hydration during acyclovir therapy to reduce risk of crystalluria and renal dysfunction. 6
• Acyclovir does not eradicate latent virus and does not prevent future recurrences after discontinuation. 1
• Topical acyclovir is substantially less effective than oral therapy and should not be used. 1
• Immunocompromised patients (especially HIV-infected) may require more aggressive therapy and are at higher risk for acyclovir-resistant strains. 1
• Acyclovir resistance is rare (<1%) in immunocompetent patients but more common in immunocompromised individuals, particularly hematopoietic stem cell transplant recipients. 7
• For acyclovir-resistant HSV, foscarnet 40 mg/kg IV three times daily or 60 mg/kg IV twice daily is the alternative. 8
• Geriatric patients have higher plasma concentrations due to age-related renal decline and may require dose reduction. 6